Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.55 |
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376413 | 0.93 | TFPI (0.56) | OPRM1OPRD1OPRK1TFPINPY1R | |
| SCHEMBL31614421 | 0.91 | OPRD1 (0.57) | OPRM1OPRD1OPRK1NPY1RNPY2R | |
| Acetic Acid SCHEMBL29981808 | 0.91 | LNPEP (0.53) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31672190 | 0.90 | NPY4R (0.60) | OPRK1NPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30271263 | 0.90 | NPY4R (0.61) | OPRD1OPRK1NPY1RNPY2RNPY4R | |
| SCHEMBL34468124 | 0.89 | TFPI (0.60) | OPRM1OPRD1OPRK1TFPI | |
| SCHEMBL29663833 | 0.89 | OPRD1 (0.53) | OPRM1OPRD1OPRK1TFPI | |
| SCHEMBL29489260 | 0.89 | OPRD1 (0.62) | OPRM1OPRD1OPRK1TFPIKISS1R | |
| SCHEMBL30647292 | 0.89 | NPY4R (0.59) | OPRK1NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30109075 | 0.88 | OPRD1 (0.52) | OPRM1OPRD1OPRK1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRM1 4101/4885OPRD1 4566/4885OPRK1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.